Wild-type RAS signaling is an essential therapeutic target in RAS -mutated cancers
Science Signaling · 2025
DOI: 10.1126/scisignal.adx5186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Signaling, 2025. Verfasst von Nancy E Sealover und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA. Hauptthemen laut MEDLINE: ras Proteins, Signal Transduction, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Mutated RAS proteins activate downstream effector pathways (RAF-MEK-ERK and PI3K-AKT) to drive oncogenic transformation and progression. Because RAS family members differentially engage these pathways, combined inhibition of both pathways is required to effectively treat RAS -mutated cancers. Here, we found that this was due to signaling contributed by wild-type RAS family members that activated an effector pathway that was poorly engaged by the mutant RAS family member. Wild-type KRAS and NRAS promoted RAF-MEK-ERK signaling in cells expressing mutant HRAS, whereas wild-type HRAS and NRAS promoted PI3K-AKT signaling in cells expressing mutant KRAS. Combining inhibitors targeting the poorly engaged RAS effector pathways with inhibitors targeting the mutant RAS resulted in synergistic cytotoxicity in a manner that depended on wild-type RAS expression. The farnesyltransferase inhibitor tipifarnib blocked mutant HRAS-PI3K signaling and synergized with MEK inhibitors in HRAS -mutated cells, whereas KRAS G12C inhibitors blocked mutant KRAS-MEK signaling and synergized with PI3K inhibitors in KRAS G12C -mutated cells. Synergy was abolished in MEFs lacking all RAS proteins and in cancer cell lines in which nonmutated RAS family members were deleted. Our data highlight the critical role of wild-type RAS family members in supporting mutant RAS signaling and its importance as a therapeutic cotarget in RAS -mutated cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
- Department of Anatomy, Physiology, and Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
- Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21701, USA.
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
ORCID-Profile: Nancy E Sealover, Jacob M Hughes, Erin Sheffels, Joseph P LaMorte, Vainavi Gambhir, Amanda Linke, Matthew D Wilkerson, Marielle E Yohe, Robert L Kortum
Förderung
- NCI NIH HHS
Zitieren
APA
Sealover, N. E., Finniff, B. A., Hughes, J. M., Sheffels, E., Lee, H., LaMorte, J. P., Gambhir, V., Beckley, Z., Linke, A., Wilkerson, M. D., Yohe, M. E., & Kortum, R. L. (2025). Wild-type RAS signaling is an essential therapeutic target in RAS -mutated cancers. Science Signaling. https://doi.org/10.1126/scisignal.adx5186
Vancouver
Sealover NE, Finniff BA, Hughes JM, Sheffels E, Lee H, LaMorte JP, et al. Wild-type RAS signaling is an essential therapeutic target in RAS -mutated cancers. Science Signaling. 2025. doi:10.1126/scisignal.adx5186
BibTeX
@article{Sealover2025,
author = {Sealover, Nancy E and Finniff, Bridget A and Hughes, Jacob M and Sheffels, Erin and Lee, Hyun and LaMorte, Joseph P and Gambhir, Vainavi and Beckley, Zaria and Linke, Amanda and Wilkerson, Matthew D and Yohe, Marielle E and Kortum, Robert L},
title = {Wild-type RAS signaling is an essential therapeutic target in RAS -mutated cancers},
journal = {Science Signaling},
year = {2025},
doi = {10.1126/scisignal.adx5186}
}
EUVIMED